Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
Organogenesis Holdings Inc. to report Q3 2023 financial results on November 9th
Positive
Investors can access the live webcast and teleconference to discuss the results and corporate update
10/05/2023 - 07:30 AM
CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2023 financial results will be reported after the market closes on Thursday, November 9th.
Management will host a conference call at 5:00 p.m. Eastern Time on November 9th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here , or access the teleconference here . The live webcast can also be accessed via the company’s website at investors.organogenesis.com
About Organogenesis Holdings Inc. www.organogenesis.com .
When will Organogenesis Holdings Inc. report its Q3 2023 financial results?
Organogenesis Holdings Inc. will report its Q3 2023 financial results on November 9th.
How can investors participate in the conference call?
Investors can access the live webcast or teleconference to participate in the conference call.
Where can the live webcast be accessed?
The live webcast can be accessed on the company's website at investors.organogenesis.com.
How long will the webcast be available for?
The webcast will be archived on the company website for approximately one year.
Organogenesis Holdings Inc
ORGO Rankings
#4077 Ranked by Stock Gains
ORGO Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Finance, Financial Conglomerates
Country
US
City
Canton
About ORGO
headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.
